🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today we announced a major upgrade to our market-leading Guardant360 test. It now covers 10x more genomic biomarkers, including all guideline-recommended ones across advanced solid tumors, and quantifies tumor burden with 10x higher sensitivity. Details: bit.ly/3Yc68d9

Kirk shares his journey with being diagnosed with Stage IV #LungCancer and how Guardant360 helped navigate his treatment plan, allowing him to live life fully on his own terms. Catch more of Kirk's story: youtube.com/watch?v=pl9uI6…

We’re changing the game for #ColorectalCancer screening w/ the FDA approval of Shield, our blood test for people age 45+ at average risk. With Shield, we aim to get more people tested & catch more cancers early, when they’re most treatable. Read more: bit.ly/3WnfKzi

Our health outcomes study, the CAN-SCREEN model, has been accepted for publication in the Journal of Medical Economics. More details: bit.ly/3SsSAqb

Our Shield blood test is now covered by #Medicare and is commercially available in the U.S. as the first FDA-approved blood test for primary #ColorectalCancer screening.

📢 𝐉𝐮𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 📢 Discover the value of blood-based screening for #colorectalcancer in comparison to current screening modalities in our latest research article. Click the link to access the article 👉 bit.ly/3LRpTj4 #HEOR #healtheconomics #oncology

The Guardant IP legal team, together with leaders from our research and development teams, recently hosted USPTO as part of their Site Experience Education (SEE) Program. The visit provided a valuable platform to showcase our groundbreaking work & engage in meaningful dialogue.

Our COSMOS study was published today in Clinical Cancer Research, a journal of the Clinical Cancer Research. The results validate the utility of our Guardant Reveal blood test for predicting #ColorectalCancer recurrence without the complexity of prior tissue analysis. Read more:

Today we announced our second quarter financial results and updated guidance for the year. Full press release: bit.ly/3ArDmLG

A more pleasant way to screen for #ColonCancer deserves a pleasant website experience. Introducing ShieldCancerScreen.com — your go-to source to learn more about our FDA-approved Shield test and access valuable resources.

Last week, our teams came together for a fantastic “Making History” event, where we celebrated two major #Milestones: the upgrade of Guardant360 on our Infinity platform and the FDA approval of our Shield blood test. A heartfelt #ThankYou to every Guardant employee. Your

Today we announced that we will proudly ring the Nasdaq opening bell on August 28 to celebrate the launch of our Shield blood test for #ColorectalCancer screening. Full release: bit.ly/4dwCpAI Watch the bell ringing live next Wednesday at 8:30am ET:

Team Guardant proudly came together in Cleveland to #WalkLoud at the Colorectal Cancer Alliance’s Walk to End Colon Cancer. What an inspiring event to unite to raise funds and awareness of #ColorectalCancer!

Welcoming Guardant Health to the Nasdaq Exchange Opening Bell. x.com/i/broadcasts/1…

By ringing this morning's bell, we celebrate another pivotal moment in our journey to conquer cancer with data with the FDA approval of our Shield blood test. #ThankYou to our dedicated team, partners, and supporters who have made this achievement possible!

Discover the work behind our mission to conquer cancer with data as part of the Global Health documentary series, exploring innovative solutions to pressing global health issues.

Join us next Wednesday at the 14th Annual Clinical Biomarkers & World CDx Summit for an engaging plenary session on enhancing the predictive power of liquid biopsy with a methylation-based approach to treatment response monitoring. More details: world-cdx.com

We’re pleased to announce our partnership with Policlinico Gemelli, establishing one of the first liquid biopsy testing facilities in Italy. The collaboration aims to expand global access to innovative cancer diagnostics by offering our Guardant 360 CDx testing platform to